Pharma BD Deal Intelligence
J&J paid $13.1B for Shockwave Medical's intravascular lithotripsy technology—a bet that sonic pressure waves can become the standard for treating calcified coronary and peripheral artery disease. The acquisition targeted a $7B+ addressable market in interventional cardiology.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
J&J acquired Shockwave Medical for $13.1B for medical device manufacturing.
Johnson and Johnson sealed the deal to acquire Shockwave Medical for $13.1 billion, adding the only commercially available intravascular lithotripsy platform…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
J&J acquired Shockwave Medical for $13.1B for medical device manufacturing.
The Shockwave C2 / C2+ Coronary Intravascular Lithotripsy (IVL) catheter, FDA PMA approved February 2021 for severely calcified coronary lesions, uses sonic pressure waves to modify calcium before stent placement and is the only IVL device approved for coronary use — giving it an MOA-exclusive class. The competitive landscape splits across three calcium-modification MOA classes. Rotational/orbital atherectomy (plaque ablation via high-speed burr or eccentric crown): Boston Scientific's Rotablator (rotational atherectomy, acquired via Boston Scientific portfolio) and Abbott/Cardiovascular Systems Inc.'s Diamondback 360 Coronary Orbital Atherectomy System (FDA approved 2013 for coronary) are the primary competing MOA; these represent the current standard for heavily calcified lesions but carry perforation and slow-flow risk. Excimer laser atherectomy (photoacoustic ablation): Philips/Spectranetics ELCA (Excimer Laser Coronary Atherectomy) catheter, approved for in-stent restenosis and complex lesions. Specialty scoring/cutting balloons (surface modification, not calcium fracture): Boston Scientific AngioSculpt and Wolverine cutting balloon, Abbott's Chocolate XD, OrbusNeich Scoreflex. Pre-IVL standard-of-care non-compliant high-pressure balloons remain universal adjuncts. Per J&J's 2024 Form 10-K disclosure supporting the $13.1B Shockwave acquisition, IVL's differentiated safety profile vs. atherectomy drives adoption; CSI/Abbott orbital atherectomy is the primary franchise threat. Source: FDA Shockwave C2 PMA approval.
The Shockwave S4 / M5+ Peripheral Intravascular Lithotripsy (IVL) catheter, FDA 510(k) cleared (original M5 PMA 2016, S4 variants follow-on) for calcified peripheral arterial disease, uses sonic pressure waves to modify medial and intimal calcium in femoropopliteal, iliac, and below-the-knee vessels. The peripheral calcium-modification competitive landscape splits across four MOA classes. Directional atherectomy (blade-based plaque excision and capture): Abbott/CSI's HawkOne and TurboHawk (acquired from Medtronic divestiture), and Philips/Spectranetics Phoenix. Rotational/orbital atherectomy (high-speed abrasion): Abbott/CSI Diamondback 360 Peripheral Orbital Atherectomy System and Boston Scientific Jetstream rotational atherectomy. Excimer laser atherectomy: Philips/Spectranetics CVX-300 with Turbo-Elite and Turbo-Power peripheral laser atherectomy catheters. Drug-coated balloons and drug-eluting stents (post-modification vessel prep/treatment, adjacent MOA): Medtronic IN.PACT Admiral DCB, Becton Dickinson/Bard Lutonix DCB, Boston Scientific Ranger DCB, and Cook Medical Zilver PTX drug-eluting stent — these frequently follow IVL or atherectomy for sustained patency. Specialty scoring balloons: Boston Scientific AngioSculpt PTA, Abbott Chocolate PTA. Per J&J's 2024 Form 10-K, Shockwave peripheral IVL generated ~$200M+ in 2023 revenue; Abbott/CSI orbital atherectomy is the principal franchise threat in calcified PAD. Source: FDA Shockwave M5 510(k).
J&J closed acquisition at $335/share for ~$13.1B EV, adding IVL technology to MedTech cardiovascular portfolio.
Shockwave operates as BU within J&J MedTech Cardiovascular, targeting $1B+ annual sales platform.
Shockwave fueled double-digit CV growth and outperformed deal model estimates from diligence.
J&J leveraged Shockwave IVL platform for cardiovascular intervention markets beyond coronary and peripheral arteries.
Shockwave outperformed deal model in year one, driving double-digit CV growth. First-in-class IVL tech has clear expansion runway.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Shockwave Medical (this deal) | 2024 | $13.1B | 76 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2024 deals · Johnson & Johnson deals · Cardiovascular deals